mTOR inhibition leads to Src-Mediated EGFR internalisation and degradation in glioma cells

Epidermal Growth Factor receptor (EGFR) is a tyrosine kinase receptor widely expressed on the surface of numerous cell types, which activates several downstream signalling pathways involved in cell proliferation, migration and survival. EGFR alterations, such as overexpression or mutations, have bee...

Descripción completa

Detalles Bibliográficos
Autores: Colella, Barbara, Colardo, Mayra, Iannone, Gianna, Contadini, Claudia, Saiz Ladera, Cristina, Fuoco, Claudia, Barilà, Daniela, Velasco Díez, Guillermo, Segatto, Marco, Di Bartolomeo, Sabrina
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/7940
Acceso en línea:https://hdl.handle.net/20.500.14352/7940
Access Level:acceso abierto
Palabra clave:577.112
576.3
616. 831-006.484
mTOR
EGFR
Glioma
Autophagy
Oncología
Biología celular (Biología)
Bioquímica (Biología)
3201.01 Oncología
2407 Biología Celular
2302 Bioquímica
Descripción
Sumario:Epidermal Growth Factor receptor (EGFR) is a tyrosine kinase receptor widely expressed on the surface of numerous cell types, which activates several downstream signalling pathways involved in cell proliferation, migration and survival. EGFR alterations, such as overexpression or mutations, have been frequently observed in several cancers, including glioblastoma (GBM), and are associated to uncontrolled cell proliferation. Here we show that the inhibition of mammalian target of Rapamycin (mTOR) mediates EGFR delivery to lysosomes for degradation in GBM cells, independently of autophagy activation. Coherently with EGFR internalisation and degradation, mTOR blockade negatively affects the mitogen activated protein/extracellular signal-regulated kinase (MAPK)/ERK pathway. Furthermore, we provide evidence that Src kinase activation is required for EGFR internaliation upon mTOR inhibition. Our results further support the hypothesis that mTOR targeting may represent an effective therapeutic strategy in GBM management, as its inhibition results in EGFR degradation and in proliferative signal alteration.